Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer’s Cipro CF Drug Gets Orphan Designation | Contract Pharma

What are you searching for?

Sign in

Bayer’s Cipro CF Drug Gets Orphan Designation

Bayer HealthCare Pharmaceuticals was granted an orphan drug designation by the FDA for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare Pharmaceuticals was granted an orphan drug designation by the FDA for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. Ciprofloxacin DPI is an investigational drug–device combination that combines ciprofloxacin dry powder formulated using Novartis’ PulmoSphere technology with a delivery inhaler. Ciprofloxacin DPI is in Phase II development and is being studied for its safety and potential to improve lung function in patients with CF.

“There continue to be significant unmet medical needs for people with cystic fibrosis,” said Shannon Campbell, vice president and general manager, Oncology and General Medicine, Bayer HealthCare Pharmaceuticals. “We are pleased to receive the orphan drug designation from the FDA for ciprofloxacin DPI, which we are researching as a potential treatment option for management of pulmonary infections due to P. aeruginosa in CF patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters